Research & Development: Page 12
-
Permission granted by Iovance Biotherapeutics
Behind the breakthrough cancer therapy that just won a historic FDA nod
The first-of-its-kind TIL therapy for solid tumors developed by Iovance Biotherapeutics won FDA approval last week.
By Kelly Bilodeau • Feb. 21, 2024 -
Courtesy of Kite Pharma, Inc.
Kite’s next-gen CAR-T aims include quicker production and more disease targets
While buzz builds around “off the shelf” CAR-T cell therapies, Kite is staying competitive with a shorter manufacturing turnaround and a focus on broadening applications.
By Kelly Bilodeau • Feb. 20, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
Permission granted by Avenga
Sponsored by AvengaValue and potential of IoT and AI for chronic diseases treatment
A significant growth is predicted for both AI and IoT in healthcare. By 2030, the AI market is expected to reach $187.95 billion USD, while the IoT market is projected to climb even higher to $312.7 billion USD.
By Olena Domanska, Data Science Engineering Manager at Avenga • Feb. 20, 2024 -
Stock via Getty Images
Pharma CFOs need R&D vigilance in tough economic times
Belt tightening and streamlined portfolios are critical in 2024 amid continued economic uncertainty.
By Amy Baxter • Feb. 16, 2024 -
Courtesy of Biogen
The roadblocks faced by Biogen are many, but execs point to an R&D-focused turnaround
A disappointing few years for Biogen have led leadership to use new drug launches as fuel for an about-face.
By Michael Gibney • Feb. 15, 2024 -
stock via Getty Images
‘Hey, AI: Is Zoloft effective for me?’ Tech’s foray into predictive prescribing
Researchers are unleashing the powers of AI for precision medicine, drug development and more.
By Alexandra Pecci • Feb. 15, 2024 -
Win McNamee via Getty Images
FDA inches closer to defining its regulatory role in AI
Commissioner Dr. Robert Califf signals how the FDA will consider AI in drug development and how the agency may use the emerging technology in the future.
By Amy Baxter • Feb. 12, 2024 -
iStock via Getty Images
A new (old) mind-opening tool in the fight against Alzheimer’s disease
A new use for an existing ultrasound technology is seeing early success in getting medications past the blood-brain barrier.
By Kelly Bilodeau • Feb. 12, 2024 -
Permission granted by Astellas
Astellas’ science chief on the leap into new technologies
After a big 2023, Yoshi Shitaka said the company is banking on gene therapies, KRAS degraders and more to keep the momentum.
By Meagan Parrish • Feb. 9, 2024 -
iStock via Getty Images
Big Pharma players Amgen, Roche and Pfizer seek to follow in Novo and Lilly’s weight loss footsteps
While Novo Nordisk and Eli Lilly have a sizable lead in the quickly expanding GLP-1 market, Big Pharma peers are looking for a way in.
By Michael Gibney • Feb. 8, 2024 -
Stock via Getty Images
Vaxxinity is brewing up meds for a spacefaring future
The biotech’s bone- and muscle-building treatments could someday help humans reach other planets.
By Kelly Bilodeau • Feb. 5, 2024 -
Permission granted by City of Hope
Immunotherapy changed the cancer treatment landscape. Is the gut microbiome the next frontier?
The president of L.A.’s City of Hope Cancer Center believes the current state of cancer treatments can be greatly improved with a peek into the gut’s many mysteries.
By Michael Gibney • Jan. 31, 2024 -
Ricardo Ceppi via Getty Images
Co-inventor of AZ COVID-19 shot pivots from vaccine-linked name
Barinthus Biotherapeutics wants to be known for more than its pandemic ties, CEO Bill Enright said.
By Alexandra Pecci • Jan. 30, 2024 -
Stock via Getty Images
Tonix closes in on the first new fibromyalgia drug in more than a decade
In addition to the chronic disease, the non-opioid drug may have applications in other painful conditions.
By Kelly Bilodeau • Jan. 29, 2024 -
Permission granted by Amylyx
Q&A‘1 plus 1 equals 3’ — the co-CEO model in pharma
Amylyx Pharmaceuticals’ co-founders and co-CEOs Josh Cohen and Justin Klee explain their approach to dual leadership and why it can be a good fit in life sciences.
By Meagan Parrish • Jan. 26, 2024 -
Dan Kitwood/Getty Images via Getty Images
King’s prostate surgery puts spotlight on men’s health — and new cancer treatments on the way
The publicly announced procedure has highlighted one of the most prevalent and deadly cancers among men, and the treatments being developed to combat it.
By Michael Gibney • Jan. 25, 2024 -
Stock via Getty Images
The biggest questions hanging over pharma in 2024
Key trends on the horizon in the life sciences this year.
By Meagan Parrish • Jan. 25, 2024 -
Stock via Getty Images
Breast cancer tops list of most studied diseases
The most studied diseases last year included three types of cancer as research into COVID-19 fell sharply in the post-pandemic era.
By Kelly Bilodeau • Jan. 24, 2024 -
Stock via Getty Images
Controversial challenge trials offer unparalleled innovation — with ethical bumps
Demand for infectious disease treatments is projected to grow and challenge trials, when done right, could speed drug development.
By Kelly Bilodeau • Jan. 22, 2024 -
Getty Images via Getty Images
The hunt for an elusive universal coronavirus vaccine
A new study shows that a universal vaccine would lead to huge financial and mortality wins during a pandemic, but development has been slow going.
By Alexandra Pecci • Jan. 22, 2024 -
Permission granted by Takeda Pharmaceuticals
Five years after closing the Shire deal, Takeda is ready to harvest from its latest reinvention
Amid criticisms of Takeda’s megamerger, the company’s CSO said it has built a pipeline that will deliver.
By Meagan Parrish • Jan. 19, 2024 -
Stock via Getty Images
Pharma takes a gut check of microbiome drugs
On the heels of two FDA approvals for microbiome-based therapies, interest in the space is gaining steam.
By Kelly Bilodeau • Jan. 16, 2024 -
Stock via Getty Images
OpinionPharma execs sound off on trends and policies they’re tracking in 2024
From regulatory concerns to leadership skills, pharma leaders at JPM shared how they’re approaching the coming year.
By Meagan Parrish • Jan. 12, 2024 -
Stock via Getty Images
Opinion // Year in PreviewPharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials
As advanced therapies and patient perspectives strengthen their foothold in R&D, pharma is poised to deliver impactful treatments in record time.
By Meagan Parrish • Jan. 11, 2024 -
Shutthiphong Chandaeng via Getty Images
Believe the hype? Mixed signals from AI’s impact on drug development
Although AI’s failure rates in drug development still leave room for improvement, today’s missteps feed tomorrow’s successes.
By Kelly Bilodeau • Jan. 10, 2024
Previous
